

Drug Injury Watch: The Drug-Induced Pancreatitis Safety Problem That Hangs Around Victoza Gets Another Look

The Relatively New Diabetes Medication Victoza From Novo Nordisk Was Only Approved By FDA In 2010

(Posted by Tom Lamb at www.DrugInjuryWatch.com on November 15, 2012)

SUMMARY: Victoza (liraglutide) is one of only two GLP-1 agonists currently on the market, the other being Byetta (exenatide).

The drug safety controversy which surrounds Victoza and [Byetta](#), both, includes the issue of whether it is the diabetes drug or the diabetes which causes pancreas disease and, in particular, acute pancreatitis, hemorrhagic pancreatitis, or necrotizing pancreatitis.

[\[Read this article in full at original source\]](#)

Earlier articles by attorney Tom Lamb on the Drug Injury Watch blog:

- [Pradaxa Safety Debate Continues During November 2012 With Many Different Conclusions And Positions](#)
- [Fosamax And Femur Fractures: Two New 2012 Medical Journal Articles Go From One Diagnosis To Many Long-Term Outcomes Of Patients](#)
- [Fresenius GranuFlo Product Has Been Associated With Heart Problems And Cardiopulmonary Arrest During Dialysis Treatment](#)
- [NuvaRing: Plaintiffs' Expert Reports Made Available By New Jersey Judge Based On Public's Right Of Access To Judicial Proceedings](#)
- [New Obesity Drug Qsymia / Qsiva Gets Negative Opinion By European Medicines Agency \(EMA\)](#)

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.

<http://www.DrugInjuryWatch.com>